AI Visibility Scorecard
Developing immuno-oncology and ADC breakthrough therapies
nectintx.com · Healthcare
Borderline visible. AI bots can crawl Developing immuno-oncology and ADC breakthrough therapies, but the structured-data signals are thin - you are at real risk of being skipped when buyers ask ChatGPT, Claude, or Perplexity for a recommendation.
AI engines read this profile 3 times
Meta AI · Claude
#768,597 of 923,684 in Healthcare for AI visibility
4
AEO Visibility
iNear-invisible · 3.8/10
0
Muse Index Score
iAI agent readiness
Basic · 0/100
0
AI Adoption
iNone detected · 0/100
About Developing immuno-oncology and ADC breakthrough therapies
from our crawl and measurement
"NectinTX develops next-generation delivery platforms for immuno-oncology and precision therapeutics." That is how Developing immuno-oncology and ADC breakthrough therapies introduces itself. When AI engines look at it, they find little to work with. It scores 3.8 out of 10.
Our crawl found structured data on the page (WebPage, ImageObject, BreadcrumbList) and a readable heading structure. It is missing an llms.txt file and a sitemap.
The 6 signals AI reads
Strong · Good · Fair · Weak
Structured Data
Weak
Organization / LocalBusiness JSON-LD that AI can read.
Content Structure
Fair
Clear headings and answer-style content.
Entity Clarity
Good
How clearly your brand identity reads to AI.
E-E-A-T Signals
Experience, Expertise, Authority, Trust
Weak
Experience, Expertise, Authority, Trust markers.
Technical AEO
Good
robots.txt, llms.txt, and AI-bot crawl access.
AI Discoverability
Fair
Sitemaps and entity links AI can follow.
Off-page authority
How the web signals your brand to AI
Backlinks
Weak
No inbound links found yet.
Domain Authority
Weak
Little domain authority yet.
Reference Presence
Weak
Not in AI knowledge graphs yet.
News & Press
Weak
No press coverage found yet.
Community
Weak
No community discussion yet.
Social Mentions
Weak
No social discussion found yet.
What this score means
Your AEO score measures whether AI search engines - ChatGPT, Claude, Perplexity, Gemini - can actually read your site and cite it in answers. Roughly two-thirds of sites are invisible to them. At 3.8/10, Developing immuno-oncology and ADC breakthrough therapies is crawlable but under-signaled - fixable, and the signals above are where to start.
Is this your brand?
The exact fixes for Developing immuno-oncology and ADC breakthrough therapies
Which AI engines already crawl you
Free AI bot monitoring: see every AI crawler that visits you
How to Get Your Brand Cited by ChatGPT, Gemini, and Claude: The Complete AEO Guide
The search landscape has fundamentally shifted. While Google still dominates, millions of users now ask questions to ChatGPT, Gemini, and Claude instead of typing into a search bar.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for Developing immuno-oncology and ADC breakthrough therapies.
Source & Attribution
Scored by Engagemii on August 12, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/nectintx
Cite this score: Engagemii (2026). "AEO Score for Developing immuno-oncology and ADC breakthrough therapies." Retrieved from https://engagemii.com/aeo/brands/nectintx
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - The Answer Engine Optimization (AEO) Platform